{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Sheet1"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":6,"n_cols":17,"rows_kept":6,"merged":[[0,2,0,16]],"flags":["formulas_cached_only"]}
[null,null,"Table 2.  A literature review of researches of polidocanol foam injection sclerotherapy in patients with antithrombotic therapy combined with mixed hemorrhoid bleeding"]
[null,null,"Researcher, date","Subjects (N)","Age (years）","Gender (M/F)","Goligher grade","Sclerosant","Remission of symptoms","Maintenance of symptoms","Efficacy rate","Severe complication","Mild complication","No complication","Incidence of severe complications","recurrence","recurrence rate"]
[null,null,"Current report",7,"80.1±12.4","4M/3F","Ⅱ to III","3 % polydocanol foam",7,0,{"v":1,"d":"100.00%"},0,0,7,{"v":0,"d":"0.00%"},1,{"v":0.1429,"d":"14.29%"}]
[null,null,"Salgueiro et al\n(2021)[19]",73,"70.1 ± 12.0","42M/31F","I to III","3 % polydocanol foam",69,4,{"v":0.9451999999999999,"d":"94.52%"},1,3,66,{"v":0.0137,"d":"1.37%"},13,{"v":0.17809999999999998,"d":"17.81%"}]
[null,null,"Santos et al\n(2019)[30]",18,"67.4(51-82)","15M/3F","I to III","3 % polydocanol foam",17,1,{"v":0.9444,"d":"94.44%"},1,2,15,{"v":0.0556,"d":"5.56%"},"Not available","Not available"]
[null,null,"Figueiredo et al\n(2022)[31]",45,"Not available","Not available","I to III","2 % polydocanol foam",40,5,{"v":0.8889,"d":"88.89%"},"Not available","Not available","Not available","Not available","Not available","Not available"]